Skip to content
Evigrade
ModerateImmunosuppressants. Calcineurin inhibitors×Antianginal – late sodium current inhibitor

Updated · Methodology

Mechanism

Ranolazine is a substrate of the transporter P-glycoprotein (P-gp), and P-gp inhibitors, including ciclosporin, raise ranolazine levels (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). The documents give no figures for ciclosporin. Verapamil, another P-gp inhibitor, raised ranolazine levels 2.2-fold (EMA). Ciclosporin also inhibits CYP3A4 (ciclosporin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), the main enzyme that metabolises ranolazine (EMA). In turn, ranolazine is a moderate to strong P-gp inhibitor and a weak CYP3A4 inhibitor, so it may raise levels of narrow-therapeutic-range drugs metabolised by CYP3A4, including ciclosporin. Levels of tacrolimus, another such drug, rose in patients after they started ranolazine (EMA).

Symptoms

Higher ranolazine levels make dizziness, nausea and vomiting more likely (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). A common and potentially serious complication of ciclosporin is a rise in serum creatinine and urea. These changes are dose-dependent, initially reversible and usually respond to a dose reduction (ciclosporin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Ciclosporin can also raise blood pressure, potassium, bilirubin and liver enzymes (AEMPS).

Management

The documents do not prohibit the combination, but adjust the ranolazine dose carefully. The European ranolazine summary of product characteristics (SmPC) names ciclosporin among P-glycoprotein (P-gp) inhibitors: give ranolazine with caution and reduce its dose if needed (ranolazine SmPC, European Medicines Agency, EMA). The US ranolazine label says to titrate ranolazine based on clinical response with P-gp inhibitors such as ciclosporin (ranolazine label, US Food and Drug Administration, FDA). Monitor ciclosporin blood levels and adjust its dose accordingly, as for other narrow-therapeutic-range drugs metabolised by CYP3A4 (EMA). The US label says the ciclosporin dose may need to be reduced (FDA). After organ transplantation, measure ciclosporin levels frequently, especially when other drugs are started or stopped. Without a transplant, when drugs that raise ciclosporin levels are added, frequent assessment of renal function and careful monitoring for ciclosporin adverse reactions may be more appropriate (ciclosporin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish ciclosporin SmPC says to take care when giving ciclosporin with drugs that are substrates of CYP3A4 and P-gp, or to avoid such combinations (AEMPS), and ranolazine is one of these substrates (EMA). Ranolazine is contraindicated if creatinine clearance is below 30 mL/min. At 30–80 mL/min, adjust its dose carefully, and monitor renal function regularly during ranolazine treatment (EMA). If dizziness, nausea or vomiting appear, reduce ranolazine to 500 mg or 375 mg twice daily, and stop it if the symptoms do not resolve (EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Ciclosporin

Other interactions with Ranolazine